Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics () on
Last Price Change open Day High 52-Week High
Volume Previous Close Day Low 52-Week Low

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2020 at 12:00 p.m.
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 2, 2020, the Compensation Committee of Esperion’s Board of Directors granted 358 restricted stock units (RSUs) to one new colleague under Esperion’s 2017 Inducement Equity Incentive Plan.
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion’s Board of Directors granted 61,705 restricted stock units (RSUs) to fifty-four new colleagues under Esperion’s 2017 Inducement Equity
Toggle Summary Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia.
Toggle Summary Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
  –  Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP –  –   Over 52- Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo –  – Bempedoic Acid is being developed as an Oral, Once-daily ATP Citrate Lyase (ACL)
Load More